Form 8-K - Current report:
SEC Accession No. 0001140361-25-009696
Filing Date
2025-03-20
Accepted
2025-03-20 16:30:29
Documents
13
Period of Report
2025-03-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20045830_8k.htm   iXBRL 8-K 28518
  Complete submission text file 0001140361-25-009696.txt   164545

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA roiv-20250316.xsd EX-101.SCH 3979
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20250316_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20250316_pre.xml EX-101.PRE 16042
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20045830_8k_htm.xml XML 4208
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 25756917
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)